Evidence map›Paper›PMID 42436127›Full record

ArticleNature communications2026

Patient-derived model capturing hypoxia and extracellular matrix remodelling of immunologically cold high-grade serous tumours.

Simona Plesselova, Hailey Axemaker, Kristin Calar, Oduduabasi Isaiah, Jared Wollman, Somshuvra Bhattacharya, Etienne Z Gnimpieba, Darci M Fink, Congzhou Wang, Hiruni Sumanasiri and 3 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Simona PlesselovaCenter for Cancer Biology Research, Sanford Research Institute, Sioux Falls, SD, USA.
Hailey AxemakerCenter for Cancer Biology Research, Sanford Research Institute, Sioux Falls, SD, USA.
Kristin CalarCenter for Cancer Biology Research, Sanford Research Institute, Sioux Falls, SD, USA.
Oduduabasi IsaiahFunctional Genomics and Bioinformatics Core, Sanford Research Institute, Sioux Falls, SD, USA.
Jared WollmanFlow Cytometry Core, Sanford Research Institute, Sioux Falls, SD, USA.
Somshuvra BhattacharyaCenter for Cancer Biology Research, Sanford Research Institute, Sioux Falls, SD, USA.
Etienne Z GnimpiebaDepartment of Biomedical Engineering, University of South Dakota, Vermillion, SD, USA.ORCID http://orcid.org/0000-0002-5338-084X
Darci M FinkDepartment of Chemistry, Biochemistry & Physics, South Dakota State University, Brookings, SD, USA.
Congzhou WangDepartment of Nanoscience and Biomedical Engineering, South Dakota School of Mines and Technology, Rapid City, SD, USA.
Hiruni SumanasiriDepartment of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, USA.
Kristina W ThielDepartment of Obstetrics and Gynecology, University of Iowa, Iowa City, IA, USA.
Maria BellSanford Health, Sanford Gynecologic Oncology Clinic, Sioux Falls, SD, USA.
Pilar de la PuenteCenter for Cancer Biology Research, Sanford Research Institute, Sioux Falls, SD, USA. pilar.puente@sanfordhealth.org.ORCID http://orcid.org/0000-0001-5953-1197

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
Wichozani-A Healthy Lifestyle for Rural American Indian Youth through Cultural and Physical Activities: A Community-Based Participatory Research StudyP20GM103443 · NIGMS · UNIVERSITY OF SOUTH DAKOTA · PI Victor Chester Huber · 2012 to 2026
$58.1M
Yeast 2 HybridP20GM103620 · NIGMS · SANFORD RESEARCH/USD · PI ROUX, KYLE J · 2013 to 2023
$24.2M
The Impact of PD-1 Inhibition on Immune-Response to ChemoradiotherapyP20GM103548 · NIGMS · SANFORD RESEARCH/USD · PI EGLAND, KRISTI A · 2012 to 2020
$20.8M
Pilot Project ProgramP30GM145398 · NIGMS · SANFORD RESEARCH/USD · PI W KEITH MISKIMINS · 2023 to 2026
$6.2M
Functional Genomics and Bioinformatics CoreP30GM154633 · NIGMS · SANFORD RESEARCH/USD · PI Kameswaran Surendran · 2024 to 2026
$4.9M
Elucidating spatiotemporal dynamics of nascent extracellular matrix in response to platinum treatment in ovarian cancerR37CA291976 · NCI · SANFORD RESEARCH/USD · PI Pilar de la Puente · 2025 to 2026
$1.1M
Attacking aggressive p53 mutants in gynecologic cancerK22CA263783 · NCI · UNIVERSITY OF IOWA · PI THIEL, KRISTINA W · 2022 to 2024
$561k
Role of extracellular matrix remodeling on high-grade serous ovarian carcinoma immune evasionR21CA259158 · NCI · SANFORD RESEARCH/USD · PI DE LA PUENTE, PILAR · 2022 to 2023
$423k
American Cancer Society (American Cancer Society, Inc.) RSG-23-1149466-01-CDPNCI NIH HHS K22 CA263783NCI NIH HHS P30 CA086862NCI NIH HHS R21 CA259158NCI NIH HHS R37 CA291976NIGMS NIH HHS P20 GM103443NIGMS NIH HHS P20 GM103548NIGMS NIH HHS P20 GM103620NIGMS NIH HHS P30 GM145398NIGMS NIH HHS P30 GM154633U.S. Department of Defense (United States Department of Defense) CA220729P1U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) K22CA263783U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P01CA278375U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA086862U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R21CA259158U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R37CA291976U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) P30GM145398U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) P30GM154633
6 · The paper itself

Abstract

High-grade serous carcinoma tumours present poor survival rates, often associated with immunologically excluded environments driven by hypoxia and extensive extracellular matrix remodelling that disrupt tumour-stromal-immune interactions. Current experimental models fail to fully capture these microenvironmental features, limiting understanding of tumour-immune dynamics and drug development. Here, we present bioengineered patient-derived tumour-immune models to mimic physiologically relevant oxygen levels and extracellular matrix remodelling. Cancer cells are co-cultured with cancer-associated fibroblasts within human plasma-3D matrices or grown on decellularized human ovaries. Immune cells are either included within the 3D constructs to study multi-cellular interactions or challenged to infiltrate the matrices. We demonstrate that intratumoural hypoxia acts as a friend and a foe enhancing the activation and cytotoxicity of CD8 + T cells while inducing stromal/matrix dysregulation associated with impaired immune infiltration. Targeting TGF-β signalling attenuates the hypoxia-driven stromal-mediated immune exclusion. These relevant models may aid the development of targeted therapies to transform immunologically cold tumours into immunogenic to benefit female patients.

Indexed as

Cystadenocarcinoma, SerousExtracellular MatrixOvarian NeoplasmsCancer-Associated FibroblastsCell HypoxiaCell Line, TumorCoculture TechniquesFemaleHumansSignal TransductionTransforming Growth Factor betaTumor MicroenvironmentTransforming Growth Factor beta

Identifiers

PMID42436127
PMCPMC13482822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.